001     270145
005     20260310111149.0
024 7 _ |a 10.1007/s12403-023-00622-4
|2 doi
024 7 _ |a 2451-9766
|2 ISSN
024 7 _ |a 1876-1658
|2 ISSN
024 7 _ |a 1876-1666
|2 ISSN
024 7 _ |a 2451-9685
|2 ISSN
024 7 _ |a altmetric:160671806
|2 altmetric
037 _ _ |a DZNE-2024-00743
082 _ _ |a 550
100 1 _ |a Faquih, Tariq O.
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Per- and Polyfluoroalkyl Substances Concentrations are Associated with an Unfavorable Cardio-Metabolic Risk Profile: Findings from Two Population-Based Cohort Studies
260 _ _ |a [Dordrecht]
|c 2024
|b Springer Netherlands
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1747922696_19988
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Per- and polyfluoroalkyl substances (PFAS) are widely used and persistent chemicals, leading to ubiquitous exposure. Although high PFAS levels have been associated with an adverse cardiovascular risk profile, the distribution of levels and relations with cardio-metabolic risk markers in the general population have not been fully characterized. We assessed the association between blood levels of perfluorooctaneic acid (PFOA), perfluorooctane sulfonic acid (PFOS), and perfluorohexanesulfonic acid (PFHxS) and a range of lipoproteins and metabolites as well as clinical lipid measurements. We used data from participants of the Netherlands Epidemiology of Obesity study (NEO) (n = 584) and the Rhineland Study (n = 1962), jointly spanning an age range of 30 to 89 years. PFAS were measured with the Metabolon HD4 platform, and lipoprotein and metabolite profiles were measured using Nightingale’s nuclear magnetic resonance-spectroscopy platform, and mainly comprised lipoprotein markers. Using linear regression analyses, we quantified age-, sex-, and education-adjusted associations of PFOA, PFOS, and PFHxS with clinical lipid measurements and 224 lipoproteins and metabolites. Higher levels of PFAS, particularly PFOS and PFHxS, were associated with higher concentrations of total lipid, cholesterol and phospholipid content in most HDL, IDL, LDL, and VLDL subclasses. The effect sizes were age-dependent for the majority of the associations, with the deleterious effects of PFAS being generally stronger in people below compared to those above median age. Our observation that in the general population even low PFAS concentrations are associated with an unfavorable lipid profile, calls for further critical regulation of PFAS substances.
536 _ _ |a 354 - Disease Prevention and Healthy Aging (POF4-354)
|0 G:(DE-HGF)POF4-354
|c POF4-354
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: pub.dzne.de
693 _ _ |0 EXP:(DE-2719)Rhineland Study-20190321
|5 EXP:(DE-2719)Rhineland Study-20190321
|e Rhineland Study / Bonn
|x 0
700 1 _ |a Landstra, Elvire N.
|0 P:(DE-2719)9000634
|b 1
700 1 _ |a van Hylckama Vlieg, Astrid
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Aziz, N. Ahmad
|0 P:(DE-2719)2812578
|b 3
700 1 _ |a Li-Gao, Ruifang
|0 P:(DE-HGF)0
|b 4
700 1 _ |a de Mutsert, Renée
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Rosendaal, Frits R.
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Noordam, Raymond
|0 P:(DE-HGF)0
|b 7
700 1 _ |a van Heemst, Diana
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Mook-Kanamori, Dennis O.
|0 P:(DE-HGF)0
|b 9
700 1 _ |a van Dijk, Ko Willems
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Breteler, Monique M. B.
|0 P:(DE-2719)2810403
|b 11
|e Last author
773 _ _ |a 10.1007/s12403-023-00622-4
|0 PERI:(DE-600)2847071-0
|p 1251 - 1262
|t Exposure and health
|v 16
|y 2024
|x 2451-9766
856 4 _ |u https://pub.dzne.de/record/270145/files/DZNE-2024-00743.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/270145/files/DZNE-2024-00743.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
876 7 _ |a #574
|c 2600
|e Hybrid-OA
|d 2026-03-09
|j DEAL
|9 2025-09-09
909 C O |o oai:pub.dzne.de:270145
|p openaire
|p open_access
|p OpenAPC_DEAL
|p driver
|p VDB
|p openCost
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9000634
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)2812578
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)2810403
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-354
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Prevention and Healthy Aging
|x 0
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-27
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EXPOS HEALTH : 2022
|d 2023-10-27
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b EXPOS HEALTH : 2022
|d 2023-10-27
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-27
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2023-10-27
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-27
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1060
|2 StatID
|b Current Contents - Agriculture, Biology and Environmental Sciences
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-27
915 p c |a APC keys set
|2 APC
|0 PC:(DE-HGF)0000
915 p c |a Local Funding
|2 APC
|0 PC:(DE-HGF)0001
920 1 _ |0 I:(DE-2719)1012001
|k AG Breteler
|l Population Health Sciences
|x 0
920 1 _ |0 I:(DE-2719)5000071
|k AG Aziz
|l Population & Clinical Neuroepidemiology
|x 1
980 1 _ |a FullTexts
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1012001
980 _ _ |a I:(DE-2719)5000071
980 _ _ |a UNRESTRICTED
980 _ _ |a APC


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21